Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.45 USD

74.45
1,834,685

+0.67 (0.91%)

Updated Aug 19, 2024 03:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments

Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.

Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails

Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.

Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $64.75 in the latest trading session, marking a +0.2% move from the prior day.

Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL

Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study

Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptomatic COVID-19.

Why Is Gilead (GILD) Down 1.8% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss

Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.

FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses

FATE reports a wider Q4 loss on increased R&D expenses.

The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Deere, T-Mobile US and Gilead Sciences

The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Deere, T-Mobile US and Gilead Sciences

Sheraz Mian headshot

Top Analyst Reports for Apple, P&G, Deere & Others

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Procter & Gamble (PG), and Deere (DE).

Stock Market News for Feb 17, 2021

The Dow booked a second straight record high on Tuesday with progress in Biden¿¿¿s $1.9 trillion coronavirus relief package and data showing COVID-19 cases dropping.

Gilead (GILD) & Galapagos Discontinue Development of IPF Drug

Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.

TEVA Stock Declines Despite Q4 Earnings and Sales Beat

TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates

Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.

Glaxo's (GSK) Rukobia Gets EU Nod for Multidrug-Resistant HIV

The approval of Glaxo's (GSK) Rukobia is based on data from the pivotal phase III BRIGHTE study. Rukobia was approved in the United States in July last year.

Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy

Bristol Myers (BMY) obtains FDA approval of CAR T cell therapy, Breyanzi, for the treatment of lymphoma.

TEVA Gears Up to Report Q4 Earnings: What's in the Cards?

On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to Q4 Earnings?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.

Roche (RHHBY) 2020 Earnings Down Due to Biosimilars, COVID-19

Roche's (RHHBY) performance in 2020 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand

Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.

The Zacks Analyst Blog Highlights: Ford, Pinterest, Peloton Interactive, Gilead Sciences and T-Mobile US

The Zacks Analyst Blog Highlights: Ford, Pinterest, Peloton Interactive, Gilead Sciences and T-Mobile US

Mark Vickery headshot

Massive Q4 Earnings Beats: Ford, Pinterest, Peloton & More

There are so many companies hitting the tape with earnings reports in the after-hours, we only have time to touch on a few of them.

Gilead Sciences (GILD) Q4 Earnings and Revenues Top Estimates

Gilead (GILD) delivered earnings and revenue surprises of 1.86% and 4.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?